BIOMAT Database Logo BIOMAT Database Logo

Current studies of liposome muramyl tripeptide (CGP 19835A lipid) therapy for metastasis in spontaneous tumors: a progress review. 1994

E G MacEwen, and I D Kurzman, and S Helfand, and D Vail, and C London, and W Kisseberth, and R C Rosenthal, and L E Fox, and E T Keller, and J Obradovich
Department of Medical Sciences, University of Wisconsin, Madison 53706.

Targeted delivery of macrophage activating agents is an attractive approach to treat micrometastatic disease. Liposome-encapsulated muramyl tripeptide phosphatidylethanolamine (L-MTP-PE) is a potent activator of monocytes/macrophages in humans, mice, and dogs. We have conducted clinical trials in dogs with malignant and highly metastatic spontaneous tumors. Presented are results of our trials evaluating L-MTP-PE in combination with surgery and chemotherapy in dogs with spontaneous osteosarcoma and hemangiosarcoma, particularly relevant malignancies having having many similarities to human cancer. Osteosarcoma dogs received chemotherapy following surgery (cisplatin q 28 days x 4). At completion of chemotherapy, dogs were randomized to receive L-MTP-PE or placebo. The L-MTP-PE group had a significantly longer median survival time compared to the placebo group (p < 0.021). Dogs with splenic hemangiosarcoma received combination chemotherapy following surgery (doxorubicin and cyclophosphamide q 21 days x 4). At the first chemotherapy, dogs were randomized to receive L-MTP-PE or placebo. The L-MTP-PE group had a significantly longer median survival time compared to the placebo group (p < 0.03). These studies show that L-MTP-PE is an effective agent for treatment of metastasis and can be safely administered in combination with chemotherapy.

UI MeSH Term Description Entries
D008175 Lung Neoplasms Tumors or cancer of the LUNG. Cancer of Lung,Lung Cancer,Pulmonary Cancer,Pulmonary Neoplasms,Cancer of the Lung,Neoplasms, Lung,Neoplasms, Pulmonary,Cancer, Lung,Cancer, Pulmonary,Cancers, Lung,Cancers, Pulmonary,Lung Cancers,Lung Neoplasm,Neoplasm, Lung,Neoplasm, Pulmonary,Pulmonary Cancers,Pulmonary Neoplasm
D010714 Phosphatidylethanolamines Derivatives of phosphatidic acids in which the phosphoric acid is bound in ester linkage to an ethanolamine moiety. Complete hydrolysis yields 1 mole of glycerol, phosphoric acid and ethanolamine and 2 moles of fatty acids. Cephalin,Cephalins,Ethanolamine Phosphoglyceride,Ethanolamine Phosphoglycerides,Ethanolamineglycerophospholipids,Phosphoglyceride, Ethanolamine,Phosphoglycerides, Ethanolamine
D011446 Prospective Studies Observation of a population for a sufficient number of persons over a sufficient number of years to generate incidence or mortality rates subsequent to the selection of the study group. Prospective Study,Studies, Prospective,Study, Prospective
D001859 Bone Neoplasms Tumors or cancer located in bone tissue or specific BONES. Bone Cancer,Cancer of Bone,Cancer of the Bone,Neoplasms, Bone,Bone Neoplasm,Neoplasm, Bone
D002945 Cisplatin An inorganic and water-soluble platinum complex. After undergoing hydrolysis, it reacts with DNA to produce both intra and interstrand crosslinks. These crosslinks appear to impair replication and transcription of DNA. The cytotoxicity of cisplatin correlates with cellular arrest in the G2 phase of the cell cycle. Platinum Diamminodichloride,cis-Diamminedichloroplatinum(II),cis-Dichlorodiammineplatinum(II),Biocisplatinum,Dichlorodiammineplatinum,NSC-119875,Platidiam,Platino,Platinol,cis-Diamminedichloroplatinum,cis-Platinum,Diamminodichloride, Platinum,cis Diamminedichloroplatinum,cis Platinum
D003520 Cyclophosphamide Precursor of an alkylating nitrogen mustard antineoplastic and immunosuppressive agent that must be activated in the LIVER to form the active aldophosphamide. It has been used in the treatment of LYMPHOMA and LEUKEMIA. Its side effect, ALOPECIA, has been used for defleecing sheep. Cyclophosphamide may also cause sterility, birth defects, mutations, and cancer. (+,-)-2-(bis(2-Chloroethyl)amino)tetrahydro-2H-1,3,2-oxazaphosphorine 2-Oxide Monohydrate,B-518,Cyclophosphamide Anhydrous,Cyclophosphamide Monohydrate,Cyclophosphamide, (R)-Isomer,Cyclophosphamide, (S)-Isomer,Cyclophosphane,Cytophosphan,Cytophosphane,Cytoxan,Endoxan,NSC-26271,Neosar,Procytox,Sendoxan,B 518,B518,NSC 26271,NSC26271
D004283 Dog Diseases Diseases of the domestic dog (Canis familiaris). This term does not include diseases of wild dogs, WOLVES; FOXES; and other Canidae for which the heading CARNIVORA is used. Canine Diseases,Canine Disease,Disease, Canine,Disease, Dog,Diseases, Canine,Diseases, Dog,Dog Disease
D004285 Dogs The domestic dog, Canis familiaris, comprising about 400 breeds, of the carnivore family CANIDAE. They are worldwide in distribution and live in association with people. (Walker's Mammals of the World, 5th ed, p1065) Canis familiaris,Dog
D004317 Doxorubicin Antineoplastic antibiotic obtained from Streptomyces peucetius. It is a hydroxy derivative of DAUNORUBICIN. Adriamycin,Adriablastin,Adriablastine,Adriblastin,Adriblastina,Adriblastine,Adrimedac,DOXO-cell,Doxolem,Doxorubicin Hexal,Doxorubicin Hydrochloride,Doxorubicin NC,Doxorubicina Ferrer Farm,Doxorubicina Funk,Doxorubicina Tedec,Doxorubicine Baxter,Doxotec,Farmiblastina,Myocet,Onkodox,Ribodoxo,Rubex,Urokit Doxo-cell,DOXO cell,Hydrochloride, Doxorubicin,Urokit Doxo cell
D006394 Hemangiosarcoma A rare malignant neoplasm characterized by rapidly proliferating, extensively infiltrating, anaplastic cells derived from blood vessels and lining irregular blood-filled or lumpy spaces. (Stedman, 25th ed) Angiosarcoma,Angiosarcomas,Hemangiosarcomas

Related Publications

E G MacEwen, and I D Kurzman, and S Helfand, and D Vail, and C London, and W Kisseberth, and R C Rosenthal, and L E Fox, and E T Keller, and J Obradovich
Unique histological changes in lung metastases of osteosarcoma patients following therapy with liposomal muramyl tripeptide (CGP 19835A lipid).
January 1992, Cancer immunology, immunotherapy : CII,
E G MacEwen, and I D Kurzman, and S Helfand, and D Vail, and C London, and W Kisseberth, and R C Rosenthal, and L E Fox, and E T Keller, and J Obradovich
Efficacy of liposomal muramyl tripeptide (CGP 19835A) in the treatment of relapsed osteosarcoma.
April 1995, American journal of clinical oncology,
E G MacEwen, and I D Kurzman, and S Helfand, and D Vail, and C London, and W Kisseberth, and R C Rosenthal, and L E Fox, and E T Keller, and J Obradovich
Liposomal muramyl tripeptide (CGP 19835A lipid) therapy for resectable melanoma in patients who were at high risk for relapse: an update.
October 1998, Cancer biotherapy & radiopharmaceuticals,
E G MacEwen, and I D Kurzman, and S Helfand, and D Vail, and C London, and W Kisseberth, and R C Rosenthal, and L E Fox, and E T Keller, and J Obradovich
Cytokine production and immune cell activation in melanoma patients treated with liposomal muramyl tripeptide (CGP 19835A lipid).
January 1993, Cancer biotherapy,
E G MacEwen, and I D Kurzman, and S Helfand, and D Vail, and C London, and W Kisseberth, and R C Rosenthal, and L E Fox, and E T Keller, and J Obradovich
Effect of ibuprofen on monocyte activation by liposome-encapsulated muramyl tripeptide phosphatidylethanolamine (CGP 19835A): can ibuprofen reduce fever and chills without compromising immune stimulation?
January 1993, Cancer immunology, immunotherapy : CII,
E G MacEwen, and I D Kurzman, and S Helfand, and D Vail, and C London, and W Kisseberth, and R C Rosenthal, and L E Fox, and E T Keller, and J Obradovich
Biologic therapy for osteosarcoma using liposome-encapsulated muramyl tripeptide.
August 1995, Hematology/oncology clinics of North America,
E G MacEwen, and I D Kurzman, and S Helfand, and D Vail, and C London, and W Kisseberth, and R C Rosenthal, and L E Fox, and E T Keller, and J Obradovich
Analysis of the antimetastatic effects of synthetic muramyl tripeptide (CGP 19835A) encapsulated in liposomes in combination with other immunomodulatory agents and chemotherapeutic drugs.
January 1993, In vivo (Athens, Greece),
E G MacEwen, and I D Kurzman, and S Helfand, and D Vail, and C London, and W Kisseberth, and R C Rosenthal, and L E Fox, and E T Keller, and J Obradovich
Combination therapy with ifosfamide and liposome-encapsulated muramyl tripeptide: tolerability, toxicity, and immune stimulation.
April 1995, Journal of immunotherapy with emphasis on tumor immunology : official journal of the Society for Biological Therapy,
E G MacEwen, and I D Kurzman, and S Helfand, and D Vail, and C London, and W Kisseberth, and R C Rosenthal, and L E Fox, and E T Keller, and J Obradovich
Liposome-encapsulated muramyl tripeptide: a new biologic response modifier for the treatment of osteosarcoma.
January 1993, Cancer treatment and research,
E G MacEwen, and I D Kurzman, and S Helfand, and D Vail, and C London, and W Kisseberth, and R C Rosenthal, and L E Fox, and E T Keller, and J Obradovich
Beneficial effect of liposome-encapsulated muramyl tripeptide in experimental septicemia in a porcine model.
January 1991, Infection and immunity,
Copied contents to your clipboard!